Health Canada
Symbol of the Government of Canada
Consumer Product Safety

Incident Report

Subform I: General Information

1. Report Type.

New incident report

Incident Report Number: 2019-2708

2. Registrant Information.

Registrant Reference Number: M-654621-01-1

Registrant Name (Full Legal Name no abbreviations): Bayer CropScience Inc.

Address: Suite 200, 160 Quarry Park Blvd S.E.

City: Calgary

Prov / State: Alberta

Country: Canada

Postal Code: T2C 3G3

3. Select the appropriate subform(s) for the incident.

Scientific Study

4. Date registrant was first informed of the incident.

5. Location of incident.

6. Date incident was first observed.

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.


PMRA Registration No. 25763      PMRA Submission No.       EPA Registration No.


  • Active Ingredient(s)

7. b) Type of formulation.

Application Information

8. Product was applied?


9. Application Rate.

10. Site pesticide was applied to (select all that apply).

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?


Subform VII: Scientific Study

1. Study Reference

Title Tebuconazole: Growth Inhibition Test with the Freshwater Diatom, Navicula pelliculosa (Final Report)

Date 11-MAR-19

2. a) Is an extension needed to translate the document?


3. Type of incident identified in the study

New health or environmental hazard

4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)

The study report is entitled "Tebuconazole: Growth Inhibition Test with the Freshwater Diatom, Navicula pelliculosa" (MRID 50827301). The study reports a set of end-points for a species of non-vascular aquatic plant not previously tested for assessing risk of Tebuconazole to aquatic organisms. The reported LyC50 (96h) = 348 ug a.i./L for Navicula pelliculosa is 50% lower than the current non-vascular plant end-point. However, the new end-point is higher (lower toxicity) e than the end-points for aquatic vascular plants already considered in the current Risk assessment for Tebuconazole.

5. a) Was the study discontinued before completion?


5. b) Provide the reason for discontinuation

6. If the study is ongoing, what is the expected completion date?

For Registrant use only

7. Provide supplemental information here